Lung Cancer

Lung cancer and tobacco smoking
pp. 167-181(15)
Authors: Boyle P.; Maisonneuve P.

Increased radioresistance of an in vitro transformed human small cell lung cancer cell line
pp. 183-198(16)
Authors: Brodin O.; Arnberg H.; Bergh J.; Nilsson S.

Reliability and validity of the Functional Assessment of Cancer Therapy -- Lung (FACT-L) quality of life instrument
pp. 199-220(22)
Authors: Cella D.F.; Bonomi A.E.; Lloyd S.R.; Tulsky D.S.; Kaplan E.; Bonomi P.

CT scanning of bronchioloalveolar carcinoma: specific appearances
pp. 221-230(10)
Authors: Akata S.; Fukushima A.; Kakizaki D.; Abe K.; Amino S.

Cognitive deficits in patients with small cell lung cancer before and after chemotherapy
pp. 231-235(5)
Authors: Meyers C.A.; Byrne K.S.; Komaki R.

A randomised trial of two cisplatin-containing chemotherapy regimens in patients with Stage III-B and IV non-small cell lung cancer
pp. 237-246(10)
Authors: Erkisi M.; Doran F.; Burgut R.; Kocabas A.

Phase I study of vinorelbine and carboplatin in advanced non-small cell lung cancer
pp. 247-257(11)
Authors: Jacoulet P.; Breton J.-L.; Westeel V.; Mercier M.; Garnier G.; Depierre A.

Phase II trial of carboplatin in combination with etoposide in locally advanced large cell carcinoma and adenocarcinoma of the lung
pp. 259-262(4)
Authors: Fuentes R.; Dorca J.; Canals E.; Izquierdo A.; Beltran M.; Viladiu P.

Radiographic abnormalities and the risk of lung cancer among workers exposed to silica dust in Ontario
pp. 265-265(1)
Author: Finkelstein M.

Evolution of aerodigestive tract 13-cis-retinoid acid chemoprevention: The M.D. Anderson experience
pp. 265-265(1)
Authors: Hong W.; Benner S.; Lippman S.

Smoking habits and attitudes of medical students towards smoking and anti-smoking campaigns in the Faculty of Medicine, University of Istanbul, Turkey
pp. 265-265(1)
Authors: Cuhadaroglu C.; Erkan F.; Ertugrul E.

Bronchopulmonary precancerous and tumor diseases - Risk groups from the point of view of occupational medicine
pp. 265-266(2)
Authors: Baur X.; Marczynski B.; Rozynek P.; Voss B.

Exposure to environmental tobacco smoke and risk of lung cancer: The epidemiological evidence
pp. 266-266(1)
Authors: Tredaniel J.; Boffetta P.; Saracci R.; Hirsch A.

Passive smoking in the workplace: Classical and Bayesian meta-analyses
pp. 266-266(1)
Authors: Biggerstaff B.; Tweedie R.; Mengersen K.

Lung adenocarcinoma and indicators of asbestos exposure
pp. 266-266(1)
Authors: Mollo F.; Pira E.; Piolatto G.; Bellis D.; Burlo P.; Andreozzi A.

Radon and primary lung cancer
pp. 266-266(1)
Authors: Menard O.; Scheid P.; Anthoine D.; Martinet Y.

Risk of lung cancer among cigarette smokers in relation to tumor location
pp. 266-266(1)
Authors: Shimizu H.; Nagata C.; Tsuchiya E.; Nakagawa K.; Weng S.-Y.

Silica dust exposure and lung cancer
pp. 266-267(2)
Authors: Koskela R.-S.; Klockars M.; Laurent H.; Holopainen M.

Integrated optical density (IOD), syntactic structure analysis, and survival in operated lung carcinoma patients
pp. 267-267(1)
Authors: Kayser K.; Liewald F.; Kremer K.; Tacke M.

A mortality study of lung cancer among Swiss professional drivers: Accounting for the smoking related fraction by a multivariate approach
pp. 267-267(1)
Authors: Pfluger D.; Minder C.

Lung cancer incidence after exposure of rats to low doses of radon: Influence of dose rate
pp. 267-267(1)
Authors: Morlier J.; Morin M.; Monchaux G.; Fritsch P.; Pineau J.; Chameaud J.

Mortality of iron foundry workers. III. Lung cancer case-control study
pp. 267-267(1)
Authors: Andjelkovich D.; Shy C.; Brown M.; Janszen D.; Levine R.; Richardson R.

Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients
pp. 267-267(1)
Authors: Ryberg D.; Hewer A.; Phillips D.; Haugen A.

Deposition and retention of inhaled fibres: Effects on incidence of lung cancer and mesothelioma
pp. 267-268(2)
Author: Lippmann M.

Effect of superoxide dismutase and diethyldithiocarbamate on the induction of squamous cell carcinoma of lung with methylcholanthrene in rats
pp. 268-268(1)
Authors: Liu M.; Yu L.; Shu Q.

Primary carcinoids of the lungs - Asbestos dust-induced malignancies in the sense of occupational disease no. 4104 BeKV?
pp. 268-268(1)
Authors: Kraus T.; Kirchner T.; Raithel H.; Lehnert G.

Asthma and lung cancer by diesel exhaust
pp. 268-268(1)
Authors: Sagai M.; Ichinose T.

Lung cancer and cigarette smoking in women: A case-control study in Barcelona (Spain)
pp. 268-268(1)
Authors: Agudo A.; Barnadas A.; Pallares C.; Martinez I.; Fabregat X.; Rosello J.

Lung cancer mortality in a French cohort of hard-metal workers
pp. 268-268(1)
Authors: Lasfargues G.; Wild P.; Moulin J.; Hammon B.; Rosmorduc B.; Du Noyer C.

Dietary cholesterol, fat, and lung cancer incidence among older women: The Iowa Women's Health Study (United States)
pp. 268-269(2)
Authors: Wu Y.; Zheng W.; Sellers T.; Kushi L.; Bostick R.; Potter J.

Lung cancer in Estonia in 1968-87: Time trends and public health implications
pp. 269-269(1)
Authors: Aareleid T.; Leinsalu M.; Rahu M.; Baburin A.

Nuclear magnetic resonance relaxation times for human lung cancer and lung tissues
pp. 269-269(1)
Authors: Matsuura Y.; Shioya S.; Kurita D.; Ohta T.; Suda S.; Haida M.; Fukuzaki M.; Ohta Y.

Lung tumor induction in A/J mice and clastogenic effects in CD-1 mice of the sequence-selective DNA alkylating agents (+)-CC-1065 and (-)-CC-1065
pp. 269-269(1)
Authors: Linseman D.; Branstetter D.; Yu R.; Aaron C.

Time-related effects of enzymatic disaggregation on model human lung carcinomas
pp. 269-269(1)
Authors: Howard R.; Shroyer K.; Marcell T.; Swanson L.; Pagura M.; Mulvin D.

Human papillomavirus type 18 DNA and E6-E7 mRNA are detected in squamous cell carcinoma and adenocarcinoma of the lung
pp. 269-269(1)
Authors: Kinoshita I.; Dosaka-Akita H.; Shindoh M.; Fujino M.; Akie K.; Kato M.

Detection of c-myc and c-sis mRNA in human non-small cell lung cancer
pp. 269-270(2)
Author: Kawamata O.

Cholecystokinin-B/gastrin receptor: A novel molecular probe for human small cell lung cancer
pp. 270-270(1)
Authors: Matsumori Y.; Katakami N.; Ito M.; Taniguchi T.; Iwata N.; Takaishi T.

Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer
pp. 270-270(1)
Authors: Fong K.; Zimmerman P.; Smith P.

Biologic characterization of pleural metastases from lung adenocarcinoma: Description of the new DV90 cell line
pp. 270-270(1)
Authors: Monti F.; Szymczuk S.; Chessa L.; Prudente S.; Nicoletti G.; Fattori P.

A GRP receptor antagonist which inhibits small cell lung cancer growth
pp. 270-270(1)
Authors: Moody T.; Venugopal R.; Zia F.; Patierno S.; Leban J.; McDermed J.

Human small cell lung cancer cells express high affinity naloxone-insensitive [¹²⁵I]-endorphin binding sites
pp. 270-270(1)
Author: Taylor J.

Constitutive secretion of bioactive transforming growth factor ₁ by small cell lung cancer cell lines
pp. 270-270(1)
Authors: Fischer J.; Darjes H.; Lahm H.; Schindel M.; Drings P.; Krammer P.

Cell type-specific regulation of p53 expression in non-small cell lung carcinoma cells
pp. 270-271(2)
Authors: Maxwell S.; Zhang W.

Expression of NSE and PGP 9.5 in non-small cell lung cancers
pp. 271-271(1)
Authors: Walker C.; Burnett H.; Kenyon W.; Spedding A.

Molecular pathogenesis of lung cancer: Implications for early diagnosis by new screening tests
pp. 271-271(1)
Author: Von Knebel Doeberitz M.

Loss of heterozygosity of the human cytosolic glutathione peroxidase I gene in lung cancer
pp. 271-271(1)
Authors: Moscow J.; Schmidt L.; Ingram D.; Gnarra J.; Johnson B.; Cowan K.

Patterns of p53 mutations in squamous cell carcinoma of the lung: Acquisition at a relatively early age
pp. 271-271(1)
Authors: Zheng J.; Shu Q.; Li Z.-H.; Tsao J.-I.; Weiss L.; Shibata D.

K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas
pp. 271-271(1)
Authors: Sugio K.; Kishimoto Y.; Virmani A.; Hung J.; Gazdar A.

Tumor suppressor and immediate early transcription factor genes in non-small cell lung cancer
pp. 271-271(1)
Authors: Levin W.; Casey G.; Ramos J.; Arboleda M.; Reissmann P.; Slamon D.

Detection of intratumoral DNA heterogeneity in primary lung cancer using a multiple sampling method
pp. 272-272(1)
Authors: Mizobuchi K.; Fujita Y.; Hashikura H.; Arimoto T.; Nakagaki Y.; Goto T.

Analysis of DNA ploidy with bronchoscopic brushing specimen as a diagnostic aid for lung cancer
pp. 272-272(1)
Authors: Kim Y.; Lee S.; Chung I.; Kang Y.; Choi I.; Park K.

Correlation of p53 protein overexpression, gene mutation with prognosis in resected non-small cell lung cancer (NSCLC) patients
pp. 272-272(1)
Authors: Lee Y.; Shin D.; Kim J.; Lim H.; Chung K.; Yang W.

Lack of tissue specificity of mucin markers in a lung cancer model: Biochemical approach
pp. 272-272(1)
Authors: Bombardieri E.; Seregni E.; Bogni A.; Botti C.; Maffioli L.; Lombardo C.

Somatostatin receptor expression in lung cancer
pp. 272-273(2)
Authors: O'Byrne K.; Halmos G.; Pinski J.; Groot K.; Szepeshazi K.; Schally A.

Retinoblastoma protein in non-small cell lung carcinoma, cells arrested for growth by retinoic acid
pp. 273-273(1)
Author: Maxwell S.

Retinoblastoma protein expression in lung cancer: An immunohistochemical analysis
pp. 273-273(1)
Authors: Higashiyama M.; Doi O.; Kodama K.; Yokouchi H.; Tateishi R.

Co-localization of three neuropeptides and NADPH diaphorase in a small cell lung carcinoma cell line
pp. 273-273(1)
Authors: Fabien N.; Cespuglio R.; Burlet S.; Pages M.; Paulin C.

Absence of p16(INK4) protein is restricted to the subset of lung cancer lines that retains wildtype RB
pp. 273-273(1)
Authors: Otterson G.; Kratzke R.; Coxon A.; Kim Y.; Kaye F.

Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history
pp. 273-274(2)
Authors: Dosaka-Akita H.; Shindoh M.; Fujino M.; Kinoshita I.; Akie K.; Katoh M.; Kawakami Y.

The role of platelet-derived growth factor production by tumor-associated macrophages in tumor stroma formation in lung cancer
pp. 274-274(1)
Authors: Vignaud J.-M.; Marie B.; Klein N.; Plenat F.; Pech M.; Borrelly J.

Cytogenetic analysis of 63 non-small cell lung carcinomas: Recurrent chromosome alterations amid frequent and widespread genomic upheaval
pp. 274-274(1)
Authors: Testa J.; Siegfried J.; Liu Z.; Hunt J.; Feder M.; Litwin S.

Proliferating cell nuclear antigen and Ki-67 in lung carcinoma: Correlation with DNA flow cytometric analysis
pp. 274-274(1)
Authors: Kawai T.; Suzuki M.; Kono S.; Shinomiya N.; Rokutanda M.; Takagi K.

Genetic alterations in p53 and K-Pas in lung cancer in relation to histopathology of the turner and smoking history of the patient
pp. 274-274(1)
Authors: Ridanpaa M.; Karjalainen A.; Anttila S.; Vainio H.; Husgafvel-Pursiainen K.

Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model
pp. 274-275(2)
Authors: Fujiwara T.; De Wei Cai Georges R.; Mukhopadhyay T.; Crimm E.; Roth J.

Close correlation between restriction fragment length polymorphism of the L-MYC gene and metastasis of human lung cancer to the lymph nodes and other organs
pp. 275-275(1)
Authors: Kawashima K.; Shikama H.; Imoto K.; Izawa M.; Naruke T.; Okabayashi K.

Activation of the protein-tyrosine kinase associated with the bombesin receptor complex in small cell lung carcinomas
pp. 275-275(1)
Authors: Gaudino G.; Cirillo D.; Naldini L.; Rossino P.; Comoglio P.

Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression
pp. 275-275(1)
Authors: Fontanini G.; Vignati S.; Bigini D.; Merlo G.; Ribecchini A.; Angeletti C.

Identification of genes differentially expressed in normal lung and non-small cell lung carcinoma tissue
pp. 275-275(1)
Authors: Schraml P.; Shipman R.; Colombi M.; Ludwig C.

Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro-endocrine lung carcinomas
pp. 275-275(1)
Authors: Gouyer V.; Gazzeri S.; Brambilla E.; Bolon I.; Moro D.; Perron P.

Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: A study on host factors in relation to age at onset, gender and histological cancer types
pp. 276-276(1)
Authors: Alexandrie A.-K.; Sundberg M.; Seidegard J.; Tornling G.; Rannug A.

Transient stabilization of p53 in non-small cell lung carcinoma cultures arrested for growth by retinoic acid
pp. 276-276(1)
Authors: Maxwell S.; Mukhopadhyay T.

Distribution pattern of the basement membrane components is one of the significant prognostic correlates in peripheral lung adenocarcinomas
pp. 276-276(1)
Authors: Matsui K.; Kitagawa M.; Sugiyama S.; Yamamoto K.

Clinical study of primary lung cancer with sarcomatous components
pp. 276-276(1)
Authors: Daido K.; Arita K.; Ejima T.; Satoh R.; Fujiwara M.; Nambu S.

Cytologic characterization of bronchial epithelial changes in small cell carcinoma of the lung
pp. 276-276(1)
Authors: Boucher L.; Yoneda K.

Cytologic features of peripheral squamous cell carcinoma of the lung
pp. 276-276(1)
Authors: Kamiya M.; Uei Y.; Shimosato Y.

A phase II study testing weekly platinum derivative combination chemotherapy as second-line treatment in patients with advanced small cell lung cancer
pp. 277-277(1)
Authors: Sculier J.P.; Thiriaux J.; Bureau G.; Lafitte J.J.; Recloux P.; Brohee D.

Lung cancer pathology in smokers, ex-smokers and never smokers
pp. 277-277(1)
Authors: Muscat J.; Wynder E.

Immunostaining in the diagnosis of pulmonary neuroendocrine carcinomas: An immunohistochemical study with ultrastructural correlations
pp. 277-277(1)
Authors: Loy T.; Darkow G.; Quesenberry J.

Prognostic significance of an interface pattern of central fibrosis and tumor cells in peripheral adenocarcinoma of the lung
pp. 277-277(1)
Authors: Yamashiro K.; Yasuda S.; Nagase A.; Hirata T.; Nojima T.; Nagashima K.

Are pathologists biased by clinical information? A blinded cross-over study of the histopathological diagnosis of mesothelial tumours versus pulmonary adenocarcinoma
pp. 277-277(1)
Authors: Skov B.; Braendstrup O.; Hirsch F.; Lauritzen A.; Nielsen H.; Skov T.

The value of neuroendocrine markers in non-small cell lung cancer: A comparative immunohistopathologic study
pp. 277-278(2)
Authors: Kiriakogiani-Psoropoulou P.; Malamou-Mitsi V.; Martinopoulou U.; Legaki S.; Tamvakis N.; Vrettou E.

Comparison of autopsy, clinical and death certificate diagnosis with particular reference to lung cancer. A review of the published data
pp. 278-278(1)
Author: Lee P.

The value of immunohistochemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastatic carcinoma
pp. 278-278(1)
Authors: Grove A.; Paulsen S.; Gregersen M.

Utility of cytokeratin immunostaining in separating pulmonary adenocarcinomas from colonic adenocarcinomas
pp. 278-278(1)
Authors: Loy T.; Calaluce R.

Pulmonary blastomas. Report on two cases and literature review
pp. 278-278(1)
Authors: Schmidt W.; Leifeld H.; Hoer P.; Dewald-Schmidt M.

Advances in pathobiological research on lung carcinoma
pp. 278-278(1)
Author: Noguchi M.

Impact of neuroendocrine differentiation in non-small cell lung cancer: The LCSG experience
pp. 278-278(1)
Authors: Linnoila R.; Piantadosi S.; Ruckdeschel J.

The correlation between bronchoscopic morphology and pathologic type in bronchogenic carcinoma
pp. 279-279(1)
Authors: Lee H.; Yoo C.; Kim Y.; Han S.; Shim Y.-S.; Kim K.

Differentiation of adenocarcinoma of the lung and malignant mesothelioma: Predictive value and reproducibility of immunoreactive antibodies
pp. 279-279(1)
Authors: Guldhammer Skov B.; Lauritzen A.; Hirsch F.; Skov T.; Nielsen H.

Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer
pp. 279-279(1)
Authors: Passlick B.; Izbicki J.; Kubuschok B.; Nathrath W.; Thetter O.; Pichlmeier U.

Pathology of the pulmonary arteries in malignant neoplasms of the lung
pp. 279-279(1)
Authors: Fisseler-Eckhoff A.; Muller K.-M.

An expert system for teaching cytopathologic diagnosis of lung cancers
pp. 279-279(1)
Authors: Balko J.; Tao L.-C.

The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies
pp. 279-280(2)
Authors: Guinee D.; Fishback N.; Koss M.; Abbondanzo S.; Travis W.

Cytochemical studies to determine the histogenesis in anaplastic or poorly differentiated pulmonary tumours
pp. 280-280(1)
Authors: Pisiriciler R.; Yerci O.; Topalidis T.

Bronchogenic carcinoma presenting as a pseudopregnancy
pp. 280-280(1)
Authors: Manzi D.; Greenberg B.; Maier D.; Forouhar F.; Malchoff C.

The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer: Diagnostic yield and comparison with conventional staging methods
pp. 280-280(1)
Authors: Buccheri G.; Ferrigno D.

The role of intraoperative ultrasound in lung cancer patients
pp. 280-280(1)
Authors: Herman K.; Kolodziejski L.

An autopsy case of lung cancer metastasizing to renal cell cancer and rectal villous adenoma
pp. 280-280(1)
Authors: Takiguchi Y.; Kasamatsu N.; Hashizume I.; Hanzawa S.; Sasaki K.; Baba M.

Treatment of brain metastases from primary lung cancer
pp. 280-281(2)
Authors: Ryan G.; Ball D.; Smith J.

Impact of radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer
pp. 281-281(1)
Authors: Izbicki J.; Passlick B.; Karg O.; Bloechle C.; Pantel K.; Knoefel W.

Carcinoid tumors of the lung: Do atypical features require aggressive management?
pp. 281-281(1)
Authors: Marty-Ane C.-H.; Costes V.; Pujol J.-L.; Alauzen M.; Baldet P.; Mary H.

Coaching persons with lung cancer to report sensory pain: Literature review and pilot study findings
pp. 281-281(1)
Authors: Wilkie D.; Williams A.; Grevstad P.; Mekwa J.

Serum neuron-specific enolase and immunohistochemical markers of neuroendocrine differentiation in lung cancer
pp. 281-281(1)
Authors: O'Shea P.; Cassidy M.; Freaney R.; McCarthy P.; Fennelly J.

Percutaneous balloon pericardiotomy for management of cardiac tamponade in a patient with lung cancer and large pericardial effusion
pp. 281-282(2)
Authors: Kouvaras G.; Polydorou A.; Hatziantoniou G.

Small giant cell carcinoma of the lung diagnosed preoperatively by transthoracic aspiration cytology: A case report
pp. 282-282(1)
Authors: Nonomura A.; Mizukami Y.; Shimizu J.; Watanabe Y.; Kobayashi T.; Kamimura R.

Detection at diagnosis of tumor cells in bone marrow aspirates of patients with small-cell lung cancer (SCLC) and clinical correlations
pp. 282-282(1)
Authors: Pasini F.; Pelosi G.; Mostacci R.; Santo A.; Masotti A.; Spagnolli P.

A case of synchronous multiple lung cancer with heterogeneous histological types
pp. 282-282(1)
Authors: Akiyama Y.; Kondo H.; Miyazaki M.; Horiuchi N.; Shirono R.; Fujii Y.

Small cell carcinoma of the lung resembling pleural mesothelioma
pp. 282-282(1)
Authors: Nomura M.; Fujimura M.; Matsuda T.; Nakamura Y.; Takayanagi N.; Kitagawa M.

A case of tracheal cancer following completion pneumonectomy for double primary lung cancer
pp. 282-282(1)
Authors: Hatta T.; Ohyabu H.; Kurisu S.; Matsuda S.; Kodama A.; Eno K.

A case of small cell lung cancer with both sarcoid reaction and metastasis in the regional lymph nodes
pp. 282-282(1)
Authors: Inagaki M.; Akaogi E.; Mitsui K.; Ishikawa S.; Yamamoto T.; Ogata T.

Prognostic factors of primary lung cancer. Assessment of tumor doubling time in survival
pp. 282-282(1)
Authors: Usuda K.; Saito Y.; Aikawa H.; Chen Y.; Endo C.; Takahashi S.

Spontaneous regression of a lung carcinoma. A case report and review of the literature
pp. 282-283(2)
Authors: Martinez-Albaladejo M.; Garcia-Lopez B.; Alguacil-Garcia G.; Gonzalez-Pina B.; De Paco Moya M.

Bronchioloalveolar carcinoma with bronchorrhoea treated with erythromycin
pp. 283-283(1)
Authors: Suga T.; Sugiyama Y.; Fujii T.; Kitamura S.

Diagnostic yield of transthoracic needle aspiration biopsy following negative fiberoptic bronchoscopy in 103 patients with peripheral circumscribed pulmonary lesions
pp. 283-283(1)
Authors: Milman N.; Faurschou P.; Grode G.

Solitary pulmonary nodule: Preliminary study of evaluation with incremental dynamic CT
pp. 283-283(1)
Authors: Yamashita K.; Matsunobe S.; Tsuda T.; Nemoto T.; Matsumoto K.; Miki H.

Interobserver variation in the computed tomographic evaluation of mediastinal lymph node size in patients with potentially resectable lung cancer
pp. 283-283(1)
Authors: Guyatt G.; Lefcoe M.; Walter S.; Cook D.; Troyan S.; Griffith L.

Association between a cytochrome P450 CYPIA1 genotype and incidence of lung cancer
pp. 283-283(1)
Authors: Okada T.; Kawashima K.; Fukushi S.; Minakuchi T.; Nishimura S.

Small cell lung carcinoma in a young patient of only 17 years old. A case report
pp. 283-283(1)
Authors: Robinet G.; Gouva S.; Le Reste N.; Leroy J.; Brambilla E.; Clavier J.

Lipid pneumonia and associated bronchio-alveolar carcinoma
pp. 284-284(1)
Authors: Breton J.; Jeffredo Y.; Ranfaing E.; Clement F.; Faure E.; Garnier G.

MR imaging of bronchogenic carcinoma
pp. 284-284(1)
Author: Zhang Z.-Q.

Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay
pp. 284-284(1)
Authors: Takada M.; Masuda N.; Matsuura E.; Kasunoki Y.; Matui K.; Nakagawa K.

CYFRA 21-1: A new tumor marker for lung cancer?
pp. 284-284(1)
Authors: Lequaglie C.; Marino P.; Maioli C.; Preda F.; Ravasi G.

Analysis of the energy balance in lung cancer patients
pp. 284-284(1)
Authors: Staal-Van den Brekel A.; Schols A.; Ten Velde G.; Buurman W.; Wouters E.

Ketoconazole in the management of paraneoplastic Cushing's syndrome secondary to ectopic adrenocorticotropin production
pp. 284-284(1)
Authors: Winquist E.; Laskey J.; Crump M.; Khamsi F.; Shepherd F.

Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years
pp. 285-285(1)
Authors: Johnson B.; Linnoila R.; Williams J.; Venzon D.; Okunieff P.; Anderson G.

The value of bone marrow examination in small cell carcinoma of the lung
pp. 285-285(1)
Authors: Horlyck A.; Henriques U.; Jakobsen A.

A case report of pulmonary squamous cell carcinoma accompanying myasthenia gravis
pp. 285-285(1)
Authors: Tomoyasu H.; Tanimura S.; Bamba J.

TNF- determination in serum and pleural effusion in patients with lung cancer
pp. 285-285(1)
Authors: Scagliotti G.; Gatti E.; Ferrari G.; Mutti L.; Pozzi E.

Bronchogenic carcinoma in HIV-positive patients: Findings on chest radiographs and CT scans
pp. 285-285(1)
Authors: Fishman J.; Schwartz D.; Sais G.; Flores M.; Sridhar K.

Measurements of resting energy expenditure and body composition before and after treatment of small cell lung cancer
pp. 285-285(1)
Authors: Jebb S.; Osborne R.; Dixon A.; Bleehen N.; Elia M.

Metastasis in tongue from carcinoma of bronchus: A case report
pp. 286-286(1)
Authors: Shehab Z.; Desousa S.; Pahor A.

Fluoroscopically guided fine needle pulmonary biopsy using the ROTEX needle: Results from 890 patients with focal lung lesions
pp. 286-286(1)
Authors: Szolar D.; Preidler K.; Kugler C.; Hausegger K.; Klein G.; Popper H.

Videothoracoscopy and video-assisted small thoracotomy for the treatment of pulmonary malignancies
pp. 286-286(1)
Authors: Casadio C.; Giobbe R.; Cianci R.; Molinatti M.; Oliaro A.; Maggi G.

A case of adenocarcinoma of the lung successfully treated by combination chemotherapy with cisplatin and vindesine, resulting in a long survival without recurrence and synchronous thyroid cancer
pp. 286-286(1)
Authors: Harita S.; Kimura Y.; Okazaki M.

Small cell lung cancer presenting as a metastatic conjunctival tumor
pp. 286-286(1)
Authors: Gotoh T.; Tsujimoto S.; Hashimoto S.; Arimoto T.; Iwasaki Y.; Hiramori N.

Measurable or assessable disease in lung cancer trials: Does it matter?
pp. 286-286(1)
Authors: Jett J.; Su J.; Krook J.; Goldberg R.; Kugler J.

Preoperative evaluation of stage I and stage II non-small cell lung cancer
pp. 286-287(2)
Authors: Hatter J.; Kohman L.; Mosca R.; Graziano S.; Veit L.; Coleman M.

Prediction of probability of pneumonectomy for lung cancer using Tc-99m MAA perfusion lung imaging
pp. 287-287(1)
Authors: Chen C.-Y.; Kao C.-H.; Hsu N.-Y.; Chen C.-L.; Hsu C.-P.; Wang P.-Y.

Prognostic significance of tissue polypeptidespecific antigen (TPS) in patients with advanced non-small cell lung cancer
pp. 287-287(1)
Authors: Van der Gaast A.; Schoenmakers C.; Kok T.; Blijenberg B.; Hop W.; Splinter T.

Clinical evaluation of serum tissue polypeptidespecific antigen (TPS) in non-small cell lung cancer
pp. 287-287(1)
Authors: Pujol J.-L.; Cooper E.; Grenier J.; Purves D.; Lehmann M.; Ray P.

The clinical significance serum N-POMC level in lung cancer patients
pp. 287-287(1)
Authors: Li L.; Luo W.; Lu Z.

Survival analysis of untreated patients with non-small-cell lung cancer
pp. 287-287(1)
Authors: Vrdoljak E.; Mise K.; Sapunar D.; Rozga A.; Marusic M.

Endoscopic criteria of early squamous cell carcinoma of the bronchus
pp. 287-287(1)
Authors: Akaogi E.; Ogawa I.; Mitsui K.; Onizuka M.; Ishikawa S.; Yamamoto T.

Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma
pp. 287-288(2)
Authors: Kirsch C.-M.; Von Pawel J.; Grau I.; Tatsch K.

The role of CT and MRI in staging of the mediastinum
pp. 288-288(1)
Author: Grover F.

The early detection of second primary lung cancers by sputum immunostaining
pp. 288-288(1)
Authors: Tockman M.; Erozan Y.; Gupta P.; Piantadosi S.; Mulshine J.; Ruckdeschel J.

The adverse effect of perioperative blood transfusion in lung cancer
pp. 288-288(1)
Authors: Piantadosi S.; Moores D.; McKneally M.

p53 Immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer: A preliminary report of LCSG 871
pp. 288-288(1)
Authors: Carbone D.; Mitsudomi T.; Chiba H.; Piantadosi S.; Rusch V.; Nowak J.

Role of mediastinal staging of lung cancer
pp. 288-288(1)
Author: Thomas P.

A case of primary signet ring cell carcinoma of the lung
pp. 289-289(1)
Authors: Choi W.; Sohn J.; Kwon O.; Hur J.; Hwang J.; Han S.

Bronchogenic carcinoma: Utility of CT in the evaluation of patients with suspected lesions
pp. 289-289(1)
Authors: Primack S.; Kyung S.; Logan P.; Miller R.; Muller N.

Bronchioloalveolar cell carcinoma in solitary pulmonary nodule (SPN) with cavitary lesion
pp. 289-289(1)
Authors: Shim J.; Lee J.; Cho J.; Ihn K.; Yoo S.; Kang K.

Gingival metastasis as first sign of an undifferentiated carcinoma of the lung
pp. 289-289(1)
Authors: Peris K.; Cerroni L.; Paoloni M.; Margiotta V.; Chimenti S.

Clinical significance of S-phase fraction in small cell lung cancer
pp. 289-289(1)
Authors: Kim H.; Jung B.; Jeong E.

Inter-relationships between single carbon units' metabolism and resting energy expenditure in weight-losing patients with small cell lung cancer. Effects of methionine supply and chemotherapy
pp. 289-289(1)
Authors: Sengelov H.; Hansen O.; Simonsen L.; Bulow J.; Nielsen O.; Ovesen L.

Case report; metastasis of lung adenocarcinoma simulating a falx meningioma
pp. 289-289(1)
Authors: Akiyama Y.; Inagawa S.; Koide T.; Kojima M.; Kumai J.; Nishikawa M.

NDPK/nm23 expression and its correlation with lymph node metastasis in human lung cancer
pp. 290-290(1)
Authors: Lei W.; Zhang R.; Yan S.

CYFRA 21-1: Preliminary experiences in bronchial carcinoma and other tumors
pp. 290-290(1)
Authors: Hoefliger M.; Morant R.; Riesen W.; Baumgartner G.; Engler H.

Evaluation of intrapulmonary nodules by positron emission tomo-graphy
pp. 290-290(1)
Authors: Knopp M.; Bischoff H.

A case of small cell lung cancer associated with fulminant hepatitis B
pp. 290-290(1)
Authors: Watanabe Y.; Tanaka H.; Ogawa M.; Tanaka T.; Tanizawa M.

A case of peripheral epidermoid carcinoma showing a fungus ball-like shadow
pp. 290-290(1)
Authors: Komiya T.; Matsushima T.; Kimura M.; Koyama I.

A case of synchronous quadruple lung cancer
pp. 290-290(1)
Authors: Furukawa T.; Koyanagi K.; Soejima Y.; Sugihara M.; Yoshida T.

A case of G-CSF producing lung cancer detected on examination for leucocytosis
pp. 290-290(1)
Authors: Kokubo M.; Ishikawa K.; Tateyama K.; Sugiyama A.; Katayama M.; Takami T.

A case of rapidly growing primary lung cancer producing alphafetoprotein
pp. 290-290(1)
Authors: Kubota M.; Tsubota N.; Yoshimura M.; Murotani A.; Sakamoto T.

Diagnosis of mediastinal lymph node metastasis from primary lung cancer on MR imaging with the STIR technique - Reevaluation of usefulness: Comparison with CT, conventional MRI and MRI with the STIR technique
pp. 291-291(1)
Authors: Fujimoto K.; Meno S.; Abe T.; Edamitsu O.; Nishimura H.; Hayabuchi N.

Clinicopathological characteristics of tumor doubling time in primary lung cancer
pp. 291-291(1)
Authors: Usuda K.; Saito Y.; Aikawa K.; Sakurada A.; Chen Y.; Endo C.

The prognostic value of argyrophil nucleolar organizer regions (AgNORs) and fibronectin antibody in stage I lung cancer
pp. 291-291(1)
Authors: Gomibuchi M.; Kanno S.; Masaki Y.; Haraguchi S.; Tanaka S.; Shoji T.

Clinicopathologic features of small cell lung cancer presenting as a solitary pulmonary nodule
pp. 291-291(1)
Authors: Yamaji Y.; Yamadori I.; Fujita T.; Fujita J.; Takahara J.; Maeda M.

Features and significance of nonbacterial thrombotic endocarditis in patients with lung cancer
pp. 291-291(1)
Authors: Tamura A.; Matsubara O.; Komatsu H.; Mohri M.; Katayama T.

Anatomic basis of lymphatic spread of lung carcinoma to the mediastinum: Anatomo-clinical correlations
pp. 291-292(2)
Authors: Riquet M.; Manac'h D.; Dupont P.; Dujon A.; Hidden G.; Debesse B.

Prognostic importance of human papilloma virus typing in squamous cell papilloma of the bronchus: Comparison of in situ hybridization and the polymerase chain reaction
pp. 292-292(1)
Authors: Popper H.; El-Shabrawi Y.; Wockel W.; Hofler G.; Kenner L.; Juttner-Smolle F.

Myasthenic (Eaton-Lambert) syndrome associated with pulmonary large-cell neuroendocrine carcinoma
pp. 292-292(1)
Authors: Demirer T.; Ravits J.; Aboulafia D.

CT demonstration of calcification in carcinoma of the lung
pp. 292-292(1)
Authors: Grewal R.; Austin J.

Lung cancer with skin metastasis
pp. 292-292(1)
Authors: Terashima T.; Kanazawa M.

The value of combined assay of serum lung cancer associated anti-gens 3C₉Ag and WLA-Ag₁
pp. 292-292(1)
Author: Bai X.-F.

Diffuse infiltrating pulmonary neoplasm with an analysis of 43 cases
pp. 292-292(1)
Author: Zheng J.-X.

A suspected case of T0N1M0 small cell carcinoma of the lung
pp. 292-293(2)
Authors: Nakamura K.; Isobe T.; Okusaki K.; Niitani K.; Murakami I.; Yoshida Y.

Squamous cell carcinoma of the lung: Does the nm23 gene expression correlate to the tumor stage?
pp. 293-293(1)
Authors: Huwer H.; Engel M.; Welter C.; Dooley S.; Kalweit G.; Feindt P.

Transforming growth factor-beta 1 (TGF-1)- and 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer
pp. 293-293(1)
Authors: Maeda J.; Ueki N.; Ohkawa T.; Iwahashi N.; Nakano T.; Hada T.

Whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer
pp. 293-293(1)
Authors: Lewis P.; Griffin S.; Marsden P.; Gee T.; Nunan T.; Malsey M.

Pulmonary carcinoma metastatic to the larynx
pp. 293-293(1)
Authors: Bernaldez R.; Toledano A.; Alvarez J.; Gavilan J.

The value of measuring serum TPA levels in bronchopulmonary cancer. A comparative study with ACE, CA 19.9 and NSE levels
pp. 293-293(1)
Authors: Prevost A.; Passemard F.; Perdu D.; Vallerand H.; Deschamps F.; Lavaud F.

Adenocarcinoma of the lung with unusual invasion of metastases into the pericardium
pp. 293-293(1)
Authors: Haberbosch W.; Bohle R.; Oksche A.; Waas W.; Heinrichs C.; Morr H.

Tumor angiogenesis in human lung adenocarcinoma
pp. 293-294(2)
Authors: Yamazaki K.; Abe S.; Takekawa H.; Sukoh N.; Watanabe N.; Ogura S.

Tumor doubling time and prognostic assessment of patients with primary lung cancer
pp. 294-294(1)
Authors: Usuda K.; Saito Y.; Sagawa M.; Sato M.; Kanma K.; Takahashi S.

Serological tumor markers for small cell lung cancer and their therapeutic implications
pp. 294-294(1)
Author: Vangsted A.

Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer
pp. 294-294(1)
Authors: Icard P.; Regnard J.-F.; Essomba A.; Panebianco V.; Magdeleinat P.; Levasseur P.

Positron emission tomography of lung tumors and mediastinal lymph nodes using [¹⁸F]fluorodeoxyglucose
pp. 294-294(1)
Authors: Scott W.; Schwabe J.; Gupta N.; Dewan N.; Reeb S.; Sugimoto J.

Ability to culture resectable non-small cell lung carcinomas is correlated with recurrence
pp. 294-295(2)
Authors: Siegfried J.; Davis A.; Testa J.; Hunt J.; Keenan R.; Yousem S.

Preoperative staging of carcinoma of the bronchus: Can computed tomographic scanning reliably identify stage III tumours?
pp. 295-295(1)
Authors: White P.; Adams H.; Crane M.; Butchart E.

A small cell bronchogenic carcinoma associated with tumoral hypophosphataemia and inappropriate antidiuresis
pp. 295-295(1)
Authors: Robin N.; Gill G.; Van Heyningen C.; Fraser W.

Prognostic value of a 90kD subunit containing glycoprotein tumor-associated antigen specific immune complexes in lung cancer patients
pp. 295-295(1)
Authors: Gupta R.; Morton D.

Gastrointestinal metastases from lung cancer: Report of a case
pp. 295-295(1)
Authors: Liu N.-J.; Chiu C.-T.; Wu S.-S.; Lin S.-M.; Chen P.-C.; Wu C.-S.

Prostatic metastasis of a small cell lung cancer in a young male
pp. 295-295(1)
Authors: Madersbacher S.; Schatzl G.; Susani M.; Maier U.

Assessment of bone marrow involvement by magnetic resonance imaging in small cell lung cancer: No significant change of staging
pp. 295-296(2)
Authors: Milleron B.; Le Breton C.; Carette M.; Cadranel J.; Akoun G.

Cranial computed tomography as a part of the initial staging procedures for patients with non-small-cell lung cancer
pp. 296-296(1)
Authors: Ferrigno D.; Buccheri G.

Role of determination of serum zinc, copper, and copperzinc ratio in evaluating diagnosis, therapeutic effect and prognosis of lung cancer
pp. 296-296(1)
Author: Zhang Z.-T.

Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC)
pp. 296-296(1)
Authors: Jorgensen L.; Osterlind K.; Hansen H.; Cooper E.

The value of octreotide scintigraphy in patients with lung cancer
pp. 296-296(1)
Authors: Kwekkeboom D.; Kho G.; Lamberts S.; Reubi J.-C.; Laissue J.; Krenning E.

Lung adenocarcinoma and metastasis in cavernous bodies of the penis
pp. 296-296(1)
Authors: Ocio F.C.; Velez F.F.; Gorospe F.G.; Santos F.M.; Alfos L.G.

Fiberscopic diagnosis in lung cancer. A report of 45 cases
pp. 296-296(1)
Author: Hu J.-Z.

Combined thoracoscopy and mediastinoscopy for the evaluation of mediastinal lymph node metastasis in left upper lobe lung cancer
pp. 297-297(1)
Authors: Nakanishi R.; Mitsudomi T.; Osaki T.

Basic and clinical studies on serum cytokeratin 19 fragment assay using centocor(R) CYFRA 21-1 kit in patients with lung cancer
pp. 297-297(1)
Authors: Hamase A.; Sugimoto Y.; Maeda M.; Kitani H.; Fukuchi M.

Early and long-term results after completion pneumonectomy
pp. 297-297(1)
Authors: Massard G.; Lyons G.; Wihlm J.-M.; Fernoux P.; Dumont P.; Kessler R.

Pneumonectomy after contralateral lobectomy: Is it reasonable?
pp. 297-297(1)
Authors: Vaaler A.; Hosannah H.; Wagner R.

Some problems of tracheobronchoplasty for lung cancer in a Regional Hospital in Russia
pp. 297-297(1)
Authors: Orzheshkovsky O.; Reshetov A.; Gridnev A.; Grinchenko S.; Makrinova O.

Incidence of local recurrence and second primary tumors in resected stage I lung cancer
pp. 297-298(2)
Authors: Martini N.; Bains M.; Burt M.; Zakowski M.; McCormack P.; Rusch V.

Long-term antimicrobial prophylaxis in lung cancer surgery: Correlation between microbiological findings and empyema development
pp. 298-298(1)
Authors: Ratto G.; Fantino G.; Tassara E.; Angelini M.; Spessa E.; Parodi A.

A new procedure for right upper lobectomy of lung with recon-struction of the carina
pp. 298-298(1)
Author: Ding J.-A.

Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection
pp. 298-298(1)
Authors: Isobe T.; Hiyama K.; Yoshida Y.; Fujiwara Y.; Yamakido M.

Evaluation of prognostic significance of p53 gene alterations in patients with surgically resected lung cancer
pp. 298-298(1)
Authors: Kashii T.; Mizushima Y.; Lima C.; Noto H.; Sato H.; Saito H.

Quality-of-life following thoracotomy for lung cancer
pp. 298-298(1)
Authors: Dales R.; Belanger R.; Shamji F.; Leech J.; Crepeau A.; Sachs H.

Bronchoplastic procedures for lung cancer: Clinical study in 136 patients
pp. 299-299(1)
Authors: Kawahara K.; Akamine S.; Tsuji H.; Nakamura A.; Takahashi T.; Tagawa Y.

One hundred and one cases of bronchoplasty for primary lung cancer
pp. 299-299(1)
Authors: Tsubota N.; Yoshimura M.; Murotani A.; Miyamoto Y.; Matoba Y.

Management of regionally advanced (stage III) non-small cell lung cancer: LCSG 831
pp. 299-299(1)
Author: Eagan R.

Current status of surgical resection for lung cancer
pp. 299-299(1)
Author: Pearson E.

General principles of surgery quality control
pp. 299-299(1)
Author: Holmes E.

Prospective assessment of 30-day operative morbidity for surgical resections in lung cancer
pp. 299-299(1)
Authors: Deslauriers J.; Ginsberg R.; Piantadosi S.; Fournier B.

Quality of life in lung cancer surgical adjuvant trials
pp. 299-299(1)
Authors: Ruckdeschel J.; Piantadosi S.H.

Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large cell undifferentiated carcinoma
pp. 300-300(1)
Author: Holmes E.

What were the issues of surgical importance in lung cancer treatment in 1977; and how did they change over time?
pp. 300-300(1)
Author: McKneally M.

Surgery for bronchogenic carcinoma in the elderly: Immediate re-sults
pp. 300-300(1)
Authors: Di Giorgio A.; Arnone P.; Casali G.; Canavese A.; Cardini C.; Speciale R.

Lung cancer surgery: A critical review of the evidence
pp. 300-300(1)
Authors: Lederle F.; Niewoehner D.

Comparative evaluation of relative survival versus classical methods applied to patients with non small cell lung cancer
pp. 300-300(1)
Authors: Foucher P.; Coudert B.; Dramais-Marcel D.; Arveux P.; Camus P.; Jeannin L.

Bilateral synchronous muscle-sparing thoracotomy in the manage-ment of bilateral pulmonary neoplasms
pp. 300-300(1)
Authors: Brulatti M.; Gelsomini S.; Tonielli E.; Del Prete P.; Guernelli N.

Resection of lung cancer is justified in high-risk patients selected by exercise oxygen consumption
pp. 301-301(1)
Authors: Walsh G.; Morice R.; Putnam J.; Nesbitt J.; McMurtrey M.; Ryan M.

Preoperative risk evaluation for lung cancer resection: Predicted postoperative product as a predictor of surgical mortality
pp. 301-301(1)
Authors: Pierce R.; Copland J.; Sharpe K.; Barter C.

Surgery for brain metastases from nonsmall cell lung carcinomas and tissue cultures from the resected specimens
pp. 301-301(1)
Authors: Kodama K.; Doi O.; Higashiyama M.; Yokouchi H.; Nakagawa H.; Mori Y.

Surgery for bronchogenic cancer in patients 75 and over
pp. 301-301(1)
Authors: Manac'h D.; Riquet M.; Dujon A.; Le Pimpec-Barthes F.; Debrosse D.; Debesse B.

Phase II trial of a 75-mg/m² dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer
pp. 301-302(2)
Authors: Miller V.; Rigas J.; Francis P.; Grant S.; Pisters K.; Venkatraman E.

Chemotherapy in small cell lung carcinoma. Prognostic value of complete response in 12800 patients
pp. 302-302(1)
Authors: Lebeau B.; Chastang C.; Schuller M.; Thiberville L.; Vaylet F.; Derenne J.

Small cell lung cancer (SCLC): A randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alfa-interferon or no treatment, as maintenance therapy
pp. 302-302(1)
Authors: Tummarello D.; Graziano F.; Mari D.; Cetto G.; Pasini F.; Antonio S.

Radical radiotherapy for early nonsmall cell lung cancer
pp. 302-302(1)
Authors: Graham P.; Gebski V.; Langslands A.

Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer?
pp. 302-302(1)
Authors: Pfeiffer P.; Sorensen P.; Rose C.

Combination of cisplatin and interferon-2a (Roferon^R-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study
pp. 303-303(1)
Authors: Kataja V.; Yap A.

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer
pp. 303-303(1)
Authors: Ellis P.; Smith I.; Hardy J.; Nicolson M.; Talbot D.; Ashley S.

A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer
pp. 303-303(1)
Authors: Bitran J.; Green M.; Perry M.; Hollis D.; Herndon J.

Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer
pp. 303-303(1)
Authors: Schiller J.; Morgan-Ihrig C.; Levitt M.

Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine
pp. 303-304(2)
Authors: Joss R.; Alberto L.; Hurny C.; Bacchi M.; Leyvraz S.; Thurlimann B.

Effect of coenzyme Q₁₀ and azelastin on protecting radiation pneumonitis with lung cancer
pp. 304-304(1)
Authors: Imanaka K.; Izumiyama K.; Sakaguchi T.; Kushima T.; Okamoto Y.; Kono M.

Cyclocreatine in cancer chemotherapy
pp. 304-304(1)
Authors: Teicher B.; Menon K.; Northey D.; Liu J.; Kufe D.

Potentiation of growth inhibition due to vincristine by ascorbic acid in a resistant human non-small cell lung cancer cell line
pp. 304-304(1)
Authors: Song E.-J.; Yang V.; Chiang C.; Chao C.-K.

Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation
pp. 304-304(1)
Authors: Prendiville J.; Lorigan P.; Hicks F.; Leahy B.; Stout R.; Burt P.

The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts
pp. 304-304(1)
Authors: Van der Graaf W.; Mulder N.; Meijer C.; De Vries E.

Dose intensity of the CAVE regimen in small cell lung cancer correlates to response rate
pp. 305-305(1)
Authors: Sirzea F.; Westberg R.; Lewensohn R.; Billing B.

A Phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer
pp. 305-305(1)
Authors: Furuse K.; Kubota K.; Kawahara M.; Ogawara M.; Kinuwaki E.; Motomiya M.

A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: A regimen associated with major toxicity in patients with advanced non-small cell lung cancer
pp. 305-305(1)
Authors: Klastersky J.; Sculier J.; Ries F.; Dabouis G.; Libert P.; Schmerber J.

Standard vs. high-dose epirubicin in combination chemotherapy of small cell lung cancer (SCLC)-Results of a phase III randomized trial
pp. 305-305(1)
Authors: Kolaric K.; Oreskovic B.; Vukas D.; Cepulic E.; Dicic M.; Judina S.

Role of mdr1 and p53 expression in the chemoresistance of lung carcinomas
pp. 305-305(1)
Authors: Peoc'h M.; Brambilla E.; Moro D.; Gazzeri S.; Brambilla C.

Carboplatin plus oral etoposide in elderly patients with non small cell lung cancer. A study of the 'Groupe francais de pneumocancerologie' (GFPC)
pp. 305-306(2)
Authors: Castelnau O.; Perol M.; Vergnenegre A.; Blanchon F.; Arnaud A.; Taytard A.; Guerin J.C.; Bonnaud F.; Kleisbauer J.P.

Efficacy of combination multidrug chemotherapy (mitomycin, ifosfamide and cisplatin) and radiotherapy for treatment of brain metastases in non small cell lung cancer
pp. 306-306(1)
Authors: Cumin I.; Lacroix H.; Mahe M.; Dutin J.; Dabouis G.

Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: A FONICAP randomised phase II study
pp. 306-306(1)
Authors: Ardizzoni A.; Addamo G.; Baldini E.; Borghini U.; Portalone L.; De Marinis F.

Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines
pp. 306-306(1)
Authors: Eijdems E.; De Haas M.; Timmerman A.; Van Der Schans G.; Kamst E.; De Nooij J.

Cytotoxic effect of herbal medicine Sho-saiko-to on human lung cancer cell lines in vitro
pp. 306-306(1)
Authors: Mizushima Y.; Kashii T.; Tokimitsu Y.; Kobayashi M.

Phase III study of a combination regimen composed of cisplatin, carboplatin and etoposide against small cell lung cancer
pp. 306-306(1)
Authors: Ichiki M.; Sakurai M.; Hayashi I.

Acquired resistance and cross-resistance of gemcitabine to cisplatin or vindesine in human lung cancer xenografted in nude mice
pp. 306-306(1)
Authors: Fujita F.; Fujita M.; Fujita M.; Sakamoto Y.

Carboplatin and etoposide in extensive small cell lung cancer
pp. 307-307(1)
Authors: Viren M.; Liippo K.; Ojala A.; Helle L.; Hinkka S.; Huovinen R.

Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): Response, toxicity, performance status change and symptom relief In patients treated with cisplatin, vinblastine and mitomycin-C
pp. 307-307(1)
Authors: Tummarello D.; Graziano F.; Isidori P.; Cellerino R.

In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice
pp. 307-307(1)
Authors: Heike Y.; Takahashi M.; Ohira T.; Arioka H.; Funayama Y.; Nishio K.

Results of a clinical multicentric randomized phase II study of non-small cell lung cancer treated with vinorelbine-cisplatin versus vinorelbine alone
pp. 307-307(1)
Authors: Lorusso V.; Pezzella G.; Catino A.; Guida M.; Scoditti S.; Lorenzo R.

Inhaled recombinant interferon gamma in patients with lung cancer: Pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages and peripheral blood neutrophils and mono-cytes
pp. 307-307(1)
Authors: Halme M.; Maasilta P.; Repo H.; Ristola M.; Taskinen E.; Mattson K.

Comparative activity of navelbine, navelbine + cisplatin, and vin-desine + cisplatin in the therapy of unresectable non small cell lung carcinoma. Results of a multicentric European randomized trial including 612 patients
pp. 307-307(1)
Authors: Gonzalez Larriba J.; Alberola V.; Lianes P.; Panizo A.; Carrato A.; Munoz Quintana A.

Treatment of Non-Small cell lung cancer with ifosfamide (IFO) + 4'-Epiadriamycin (EPI) + platinum vs. IFO + EPI: A GETLAC study
pp. 307-308(2)
Authors: Bracato N.; Bruno M.; Araujo C.; Cervellino J.; Pirisi C.; Temperley G.

Phase II clinical trial of didemnin B in previously treated small cell lung cancer
pp. 308-308(1)
Authors: Shin D.; Holoye P.; Forman A.; Winn R.; Perez-Soler R.; Dakhil S.

Late phase II clinical study of RP56976 (Docetaxel) in patients with non-small cell lung cancer
pp. 308-308(1)
Authors: Kudo S.; Hino M.; Fujita A.; Igarashi T.; Arita K.; Niitani H.

Early phase II clinical study of RP56976 (Docetaxel) in patients with primary pulmonary cancer
pp. 308-308(1)
Authors: Yokoyama A.; Kurita Y.; Watanabe K.; Negoro S.; Ogura T.; Nakano M.

Antitumor activity of combination treatment combining gemcitabine with cisplatin or vindesine against human lung cancer xenografted in nude mice
pp. 308-308(1)
Authors: Fujita F.; Fujita M.; Fujita M.; Sakamoto Y.

New promising anticancer drugs for lung cancer
pp. 308-308(1)
Authors: Ariyoshi Y.; Sugiura T.

Approaches to the analysis of quality of life data: Experiences gained from a medical research council lung cancer working party palliative chemotherapy trial
pp. 308-309(2)
Authors: Hopwood P.; Stephens R.; Machin D.

Parallel assessment of glutathione-based detoxifying enzymes, O⁶-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer
pp. 309-309(1)
Authors: Oberli-Schrammle A.; Joncourt F.; Stadler M.; Altermatt H.; Buser K.; Ris H.

Plasma 5-fluorouracil and -fluoro--alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil
pp. 309-309(1)
Authors: Thiberville L.; Compagnon P.; Moore N.; Bastian G.; Richard M.; Hellot M.

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer
pp. 309-309(1)
Authors: Ihde D.; Mulshine J.; Kramer B.; Steinberg S.; Linnoila R.; Gazdar A.

Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation
pp. 309-309(1)
Authors: Thomas G.; Barrand M.; Stewart S.; Rabbitts P.; Williams E.; Twentyman P.

Therapeutic effect of carboplatin and etoposide combinative therapy on 123 lung cancer cases
pp. 309-310(2)
Authors: Shi T.; Yan J.

Response rate of small cell lung cancer treated with CE-CAP alternating chemotherapy
pp. 310-310(1)
Authors: Zhang X.; Sun Y.; Liu Y.

Gene expression of somatostatin receptor sybtypes, SSTR1 and SSTR2, in human lung cancer cell lines
pp. 310-310(1)
Authors: Fujita T.; Yamaji Y.; Sato M.; Murao K.; Takahara J.

Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer
pp. 310-310(1)
Authors: Masuda N.; Fukuoka M.; Kudoh S.; Matsui K.; Kusunoki Y.; Takada M.

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study
pp. 310-310(1)
Authors: Anderson H.; Lund B.; Bach F.; Thatcher N.; Walling J.; Hansen H.

Randomized trial comparing weekly versus 3-week chemotherapy in small- cell lung cancer: A cancer research campaign trial
pp. 310-311(2)
Authors: Souhami R.; Rudd R.; Ruiz de Elvira M.-C.; James L.; Gower N.; Harper P.

Phase II study of a continuous five-day intravenous infusion of cisplatin and etoposide with concurrent chest radiation therapy in limited stage small cell lung cancer
pp. 311-311(1)
Authors: Sugita T.; Matsunaga K.; Kobayashi H.; Horikawa S.; Suzuki Y.; Nishiyama H.

Vinorelbine (Navelbine) in non-small cell lung cancer: Future directions
pp. 311-311(1)
Author: Crawford J.

A phase II study of cisplatin, 5-fluorouracil, and leucovorin aug-mented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: Rationale and study design
pp. 311-311(1)
Authors: Vokes E.; Drinkard L.; Samuels B.; Hoffman P.; Watson S.; Bitran J.

Vinorelbine (Navelbine)/carboplatin combination therapy: Dose intensification with granulocyte colony-stimulating factor
pp. 311-311(1)
Authors: Crawford J.; O'Rourke M.; Coltman C.

Vinorelbine (Navelbine) in the adjuvant and neoadjuvant treatment of non-small cell lung cancer
pp. 311-312(2)
Authors: Viallet J.; Ayoub J.; Rousseau P.; Souhami L.; Hohneker J.; Shepherd F.

Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: A preliminary report
pp. 312-312(1)
Authors: Vokes E.; Rosenberg R.; Jahanzeb M.; Craig J.; Gralla R.; Belani C.

A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: An expanded analysis
pp. 312-312(1)
Authors: Le Chevalier T.; Pujol J.-L.; Douillard J.-Y.; Alberola V.; Monnier A.; Riviere A.

Vinorelbine (Navelbine)-A new agent for the treatment of non-small cell lung cancer: A summary
pp. 312-312(1)
Author: Coltman C.

Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer
pp. 312-312(1)
Authors: Murray N.; Coppin C.; Coldman A.; Pater J.; Rapp E.

Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer
pp. 313-313(1)
Authors: Jett J.; Maksymiuk A.; Su J.; Mailliard J.; Krook J.; Tschetter L.

Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide combination in locally advanced non-small-cell lung cancer
pp. 313-313(1)
Authors: Pujol J.-L.; Hayot M.; Rouanet P.; Le Chevalier T.

Daunorubicin efflux against a concentration gradient in non-P-glycoprotein multidrug-resistant lung-cancer cells
pp. 313-313(1)
Authors: Mulder H.; Lankelma J.; Dekker H.; Broxterman H.; Pinedo H.

DT-diaphorase as a determinant of sensitivity to adriamycin in non-small-cell lung-cancer cell lines
pp. 313-313(1)
Authors: Kasahara K.; Shibata K.; Bando T.; Numata Y.; Fujimura M.; Matsuda T.

Synergic action with octreotide and chemotherapy in Small-Cell Lung Cancer: A pilot study
pp. 313-314(2)
Authors: Soresi E.; Invernizzi G.; Boffi R.; Liuzzi A.; Borghini U.; Mantellini P.

Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: A randomised study
pp. 314-314(1)
Authors: Veronesi A.; Cartei G.; Crivellari D.; Magri M.; Della Valentina M.; Foladore S.

Low-dose chemotherapy delays relapse of a dominated and resistant sub-population in a heterogeneous human SCLC xenograft in nude mice
pp. 314-314(1)
Authors: Aabo K.; Vindelov L.; Christensen I.; Spang-Thomsen M.

Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells
pp. 314-314(1)
Authors: Smith P.; Soues S.; Gottlieb T.; Falk S.; Watson J.; Osborne R.

Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice
pp. 314-315(2)
Authors: Pinski J.; Schally A.; Halmos G.; Szepeshazi K.; Groot K.; O'Byrne K.

Comparison of effect of I.V. cisplatin (DDP) with I.V. carboplatin (CDP) in the treatment of advanced lung cancer under maximum tolerance dosages (MTD)
pp. 315-315(1)
Author: Hua X.-M.

Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer
pp. 315-315(1)
Authors: Klastersky J.; Sculier J.

Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: A European cancer centre effort
pp. 315-315(1)
Authors: Giaccone G.; Huizing M.; Huinink W.; Koolen M.; Postmus P.; Van Kralingen K.

Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer
pp. 315-315(1)
Authors: Sculier J.-P.; Paesmans M.; Libert P.; Bureau G.; Dabouis G.; Thiriaux J.

Alteration of coagulation and fibrinolysis systems after multidrug anticancer therapy for lung cancer
pp. 315-315(1)
Authors: Gabazza E.; Taguchi O.; Yamakami T.; Machishi M.; Ibata H.; Suzuki S.

Suramin interferes with auto/paracrine insulin-like growth factor I-controlled proliferative loop on human lung cancer cell lines
pp. 316-316(1)
Authors: Favoni R.; Ravera F.; Pirani P.; Ardizzoni A.; Noonan D.; de Cupis A.

[D-Arg¹,D-Phe⁵,D-Trp^7,9,Leu¹¹]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro
pp. 316-316(1)
Authors: Woll P.; Rozengurt E.

Late phase II clinical study of KW-2307 in previously untreated patients with non-small cell lung cancer
pp. 316-316(1)
Authors: Furuse K.; Kinuwaki E.; Motomiya M.; Nishiwaki H.; Hasegawa K.; Kobayashi K.

Bronchial arterial hemodynamics after thoracic irradiation therapy in lung cancer patients
pp. 316-316(1)
Authors: Nambu Y.; Tamamura H.; Ohguchi M.; Mouri M.; Kobayashi Y.; Yamanouchi K.

Establishment of a human small-cell lung-cancer subline resistant to okadaic acid
pp. 316-316(1)
Authors: Takeda Y.; Nishio K.; Kubota N.; Miura K.; Morikage T.; Ohmori T.

Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer
pp. 316-317(2)
Authors: Robert F.; Wheeler R.; Molthrop D.; Bailey A.; Chen S.

Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells
pp. 317-317(1)
Authors: Versantvoort C.; Broxterman H.; Lankelma J.; Feller N.; Pinedo H.

Palliative endobronchial brachytherapy for central lung tumors: A prospective, randomized comparison of two fractionation schedules
pp. 317-317(1)
Authors: Huber R.; Fischer R.; Hautmann H.; Pollinger B.; Wendt T.; Muller-Wening D.

Comparative assessment of three radiotherapy treatment protocols for inoperable cerebral metastases of non-small cell lung carcinoma
pp. 317-317(1)
Authors: Demange L.; Franks A.; Panis X.

Intraluminal irradiation in the treatment of malignant airway obstruction
pp. 317-317(1)
Authors: Kohek P.; Pakisch B.; Glanzer H.

International survey of radiotherapy practice for radical treatment of non-small cell lung cancer
pp. 317-317(1)
Authors: Van Houtte P.; Gregor A.; Philips P.

Three-dimensional conformal radiotherapy in bronchogenic carcinoma: Considerations for implementation
pp. 317-318(2)
Authors: Emami B.; Graham M.; Purdy J.

High dose rate intraluminal radiotherapy for carcinoma of the bronchus: Outcome of treatment of 406 patients
pp. 318-318(1)
Authors: Gollins S.; Burt P.; Barber P.; Stout R.

Hyperfractionated irradiation for non-small cell lung cancer (NSCLC) - A phase II clinical trial
pp. 318-318(1)
Authors: Fu S.; Jiang G.; Wang L.

Radiation thrapy for irresectable non-small-cell lung cancer. Preliminary results of a randomized study
pp. 318-318(1)
Authors: Exposito J.; Linares A.; Cano C.; Del Moral R.; Martinez M.; Hernandez V.

Postoperative radiation for lung cancer metastatic to the brain
pp. 318-318(1)
Authors: Armstrong J.; Wronski M.; Galicich J.; Arbit E.; Leibel S.; Burt M.

Prophylactic cranial irradiation in complete responders with small-cell lung cancer: Analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases
pp. 318-319(2)
Authors: Shaw E.; Su J.; Eagan R.; Jett J.; Maksymiuk A.; Deigert F.

The role of radiotherapy in the treatment of stage III non-small cell lung cancer: A survey of clinical practices in Lombardy, Italy, by the Airo-Lombardia Cooperative Group
pp. 319-319(1)
Authors: Palazzi M.; Valdagni R.; Poli M.; Buffoli A.; Leoni M.; Vavassori V.

The bronchoscopic brachytherapy in early stage lung cancer of hilar type
pp. 319-319(1)
Authors: Ono R.; Hirano H.; Kaneko M.

Radiotherapy planning for lung cancer: Can we do better?
pp. 319-319(1)
Authors: Atkinson C.; Hamilton C.; Wynne C.

Changes in plasma TGF levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis
pp. 319-319(1)
Authors: Anscher M.; Murase T.; Prescott D.; Marks L.; Reisenbichler H.; Bentel G.

Treatment of small cell lung cancer with combined modality treatment
pp. 319-319(1)
Author: Hirano A.

Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer
pp. 319-320(2)
Authors: Jeremic B.; Shibamoto Y.; Acimovic L.; Djuric L.

Current treatment of forms of small-cell bronchial carcinoma limited to the hemithorax
pp. 320-320(1)
Authors: Quoix E.; Jung G.; Schumacher C.; Morand G.; Pauli G.

A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: An interim toxicity analysis of the first 100 patients
pp. 320-320(1)
Authors: Ball D.; Bishop J.; Smith J.; Crennan E.; O'Brien P.; Davis S.

Concurrent chemo-radiotherapy for stage III non-small cell lung cancer
pp. 320-320(1)
Authors: Inoue R.; Takada Y.; Obayashi K.; Kado T.; Yamamoto H.; Hirota S.

Carboplatin, epirubicin, etoposide and thoracic radiotherapy in the treatment of localized small cell lung cancer
pp. 320-320(1)
Authors: Felip E.; Gallardo E.; Del Campo J.; Vidal R.; Vera R.; Bodi

A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor sup-port for advanced malignancies of the chest
pp. 320-321(2)
Authors: Vokes E.E.; Haraf D.J.; Drinkard L.C.; Hoffman P.C.; Ferguson M.K.; Vogelzang N.J.

Combined-modality treatment of small-cell lung cancer: Randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest
pp. 321-321(1)
Authors: Joss R.; Alberto P.; Bleher E.; Ludwig C.; Siegenthaler P.; Martinelli G.

Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer
pp. 321-321(1)
Authors: Choy H.; Akerley W.; Safran H.; Clark J.; Rege V.; Papa A.

Combined chemotherapy and radiotherapy: From biology to bed-side
pp. 321-321(1)
Authors: Hennequin C.; Favaudon V.; Balosso J.; Marty M.; Maylin C.

Concurrent chemotherapy (CT) and radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC): A review
pp. 321-321(1)
Author: Mirimanoff R.

The role of induction chemotherapy before radiation therapy in non-operative management of stage III NSCLC
pp. 321-322(2)
Author: Green M.

Combined multimodality treatment for non-small cell lung cancer-With special reference to pre- and post-operative adjuvant therapy
pp. 322-322(1)
Author: Watanabe Y.

Current status of neoadjuvant therapy for non-small cell lung cancer
pp. 322-322(1)
Author: Falser L.

Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung: LCSG 881
pp. 322-322(1)
Authors: Wagner H.; Lad T.; Piantadosi S.; Ruckdeschel J.

Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer: A phase 2 study of the LCSG
pp. 322-322(1)
Authors: Weiden P.; Piantadosi S.

A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy
pp. 323-323(1)
Authors: Lad T.; Piantadosi S.; Thomas P.; Payne D.; Ruckdeschel J.; Giaccone G.

Adjuvant chemotherapy for non-small cell lung cancer
pp. 323-323(1)
Author: Johnson D.

A phase 3 randomized trial of immediate combination chemotherapy vs delayed combination chemotherapy in patients with completely resected stage II and III non-small cell carcinoma of the lung
pp. 323-323(1)
Authors: Figlin R.; Piantodasi S.

Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer: An LCSG trial
pp. 323-323(1)
Authors: Feld R.; Rubinstein I.; Thomas P.

The comparison of CAP chemotherapy and radiotherapy to radio-therapy alone for resected lung cancer with positive margin or in-volved highest sampled paratracheal node (stage IIIA): LCSG 791
pp. 323-323(1)
Author: Lad T.

Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung: LCSG 773
pp. 323-323(1)
Author: Weisenburger T.

A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung: LCSG protocol 771
pp. 323-324(2)
Author: Gail M.

Re-evaluation of bronchogenic carcinoma after X-ray and chemo-therapy. The role of CT and MRI
pp. 324-324(1)
Authors: Gualdi G.; Minerva R.; Volpe A.; Polettini E.; Anaveri G.

Clinical assessment of postoperative immunochemotherapy for non-small cell lung cancer
pp. 324-324(1)
Authors: Ishii N.; Miyamoto Y.; Okada M.; Tubota N.; Yoshimura M.; Ooyabu H.

Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: Results of a phase II Southwest Oncology Group study
pp. 324-324(1)
Authors: Hazuka M.; Crowley J.; Bunn P.; O'Rourke M.; Braun T.; Livingston R.

Quality of life in patients with limited small-cell carcinoma of the lung receiving chemotherapy with or without radiation therapy, for cancer and leukemia group B
pp. 324-324(1)
Authors: Ahles T.; Silberfarb P.; Rundle A.; Holland J.; Komblith A.; Canellos G.

Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer
pp. 324-324(1)
Authors: Comella P.; Scoppa G.; Daponte A.; Musetta G.; Anania C.; Maiorino A.

Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer
pp. 325-325(1)
Authors: Deutsch M.; Crawford J.; Leopold K.; Wolfe W.; Foster W.; Herndon J.

Preoperative concurrent radiation therapy and cisplatinum continuous infusion in IIIa (N2) non small cell lung cancer. A pilot study
pp. 325-325(1)
Authors: Maggi G.; Casadio C.; Cianci R.; Oliaro A.; Molinatti M.; Bretti S.

Photodynamic therapy of lung cancer
pp. 325-325(1)
Author: Lam S.

Clarithromycin in the long-term treatment of primary lung cancer. Possibility of clarithromycin as a biological response modifier
pp. 325-325(1)
Authors: Mikasa K.; Sawaki M.; Kita E.; Hamada K.; Konishi M.; Maeda K.

Inhalation therapy of interferon-gamma against bronchoalveolar carcinoma of the lung; a case report
pp. 326-326(1)
Authors: Yano T.; Yokoyama H.; Ueda T.; Inoue T.; Asoh H.; Ichinose Y.

Selective embolization of bronchial artery with drug gelfoam in treatment of lung cancer
pp. 326-326(1)
Author: He D.-X.

Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene
pp. 326-326(1)
Authors: Osaki T.; Tanio Y.; Tachibana I.; Hosoe S.; Kumagai T.; Kawase I.

Adjuvant immunotherapy with intrapleural Streptococcus pyogenes (OK-432) in lung cancer patients after resection
pp. 326-326(1)
Authors: Lee Y.-C.; Luh S.-P.; Wu R.-M.; Lee C.-J.

Stent-implantation for stenotic malignant tracheobronchial tumors
pp. 326-326(1)
Authors: Koller H.; Kreuzer A.; Heller K.; Torzsok L.; Neumann M.I.

The strategy for therapy of lung cancer
pp. 326-326(1)
Authors: Konaka C.; Nakajima S.; Kato H.

Lung cancer
pp. 326-327(2)
Authors: Travis W.; Travis L.; Devesa S.

Extrapulmonary small cell carcinoma: A single-institution experience and review of the literature
pp. 327-327(1)
Authors: Lo R.G.; Canzonieri V.; Veronesi A.; Dal B.V.; Barzan L.; Zancanaro C.

Bronchial and thymic carcinoid tumors: A review
pp. 327-327(1)
Authors: Dusmet M.; McKneally M.

Treatment of small cell lung cancer
pp. 327-327(1)
Authors: Ueoka H.; Ohnoshi T.

Recent change of management in advanced non-small cell lung cancer
pp. 327-327(1)
Authors: Kodama N.; Kawahara M.; Furuse K.

Future directions in clinical research for lung cancer
pp. 327-327(1)
Author: Bunn P.

Evaluation of the therapeutic prognosis and long-term survivors of small cell lung cancer
pp. 327-327(1)
Authors: Nakayama H.; Yokoyama A.; Kinameri K.; Kurita Y.

Current management of unresectable non-small cell lung cancer
pp. 328-328(1)
Authors: Livingston R.; Gralla R.; Coltman C.; Crawford J.; Vokes E.

Small cell lung cancer: Analysis of factors influencing the response to treatment and survival
pp. 328-328(1)
Authors: De Wet M.; Falkson G.; Rapoport B.

Treatment of advanced non-small cell lung cancer
pp. 328-328(1)
Author: Shepherd F.

Practical approaches to the treatment of patients with extensive stage small cell lung cancer
pp. 328-328(1)
Authors: Greco F.; Hainsworth J.

Quality of life in patients with lung cancer
pp. 328-328(1)
Authors: Pavlovic N.; Pavlovic M.

Should we reestablish the lung cancer study group?
pp. 328-329(2)
Author: Rusch V.

Evaluation of a decision-support system for inoperable non-small cell lung cancer
pp. 329-329(1)
Authors: Wigren T.; Kolari P.